

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**MONDAY  
MAY 04<sup>TH</sup>**

<b>8:00 – 8:30</b>		
Registration and Joint Breakfast in Foyer, attach Posters		
<b>8:30 – 8:55</b>		
Opening of the Conference – <i>Andreas Köpke, bioExpert</i>		
<b>8:55</b>		
Development of the Life ScienceHub Mainz – <i>Tim Roos, biomindz</i>		
<b>9:00 – 9:30</b>		
<p><b>Cellular Senescence and Aging in Neurodegenerative Diseases: Opportunities for Drug Discovery?</b>  <i>Chair: Roger Sher, Stony Brook University, USA</i></p>		
<b>PANEL 09:30 – 10:30</b>		
<b>Senescence in Neurodegeneration</b>	HMGB1 mediates senescence and cognitive dysfunction in tauopathies	<b>Rakez Kaye</b> UTMB, USA
	Aging, inflammation, and neurodegeneration: Unraveling the senescent brain in Parkinson’s disease	<b>Markus Riesland</b> Stony Brook University, USA
<b>Animal Models of PD</b>	<i>In vivo</i> models for Parkinson’s disease translation: Connecting mechanism, efficacy, and biomarkers	<b>Ayşe Ulusoy</b> DZNE Bonn, Germany
<p><b>Panel Q&amp;A of Session Speakers</b>  <i>Chair: Roger Sher, Stony Brook University, USA</i></p>		
<b>10:30 – 11:30</b>		
Coffee Break, Exhibition & Poster viewing		
<b>PANEL 11:30 – 12:30</b>		
<b>New AD Mode of Action</b>	Identification of a novel A $\beta$ (pGlu3-x) targeting pathway in Alzheimer’s disease	<b>Sarah Schrepel</b> University of Leipzig, Germany
<b>New AD Mode of Action</b>	Finding the right target for A $\beta$ immunotherapy – PTM-targeting antibodies differentially mediate inflammation and phagocytosis	<b>Stefan Schilling</b> IZI Fraunhofer Inst., Germany
		Lysosome targeting in Parkinson’s disease: From pathophysiology to therapy
<p><b>Panel Q&amp;A of Session Speakers</b>  <i>Chair: Roger Sher, Stony Brook University, USA</i></p>		
<b>12:30</b>		
Lunch		

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY  
MAY 04<sup>TH</sup>**

<b>13:30</b>		
TREM2 agonism – where do we stand and what is needed for therapy? <i>Chair: Christian Haass, DZNE, LMU, Germany</i>		
<b>PANEL 14:00 – 15:00</b>		
Neuroinflammation	Brain-Shuttle mediated TREM2 PET for highly specific assessment of activated myeloid cells	<b>Matthias Brendel</b> LMU, Germany
	TREM2 activation: Harnessing the brain's immune system to treat neurodegeneration	<b>Agnes Cheong</b> Sanofi, USA
	Transport vehicle engineering improves activity of TREM2 antibodies	<b>Lihong Zhan</b> Denali, USA
Panel Q&A of Session Speakers <i>Chair: Christian Haass, DZNE, LMU, Germany</i>		
<b>15:00 – 16:00</b>		
Coffee Break, Exhibition & Poster Session (Presenters will be at their posters.) Time for One on One Meetings		
<b>PANEL 16:00 – 17:00</b>		
Neuroinflammation	Inhibition of prolyl endopeptidase to reduce neuroinflammation	<b>Franziska Richter Assencio</b> Center for Systems Neuroscience Hannover, Germany
Service Company Presentation	De-risking drug development in neurodegenerative and age-related diseases	<b>Stefan Ebner-Behnke</b> Scantox, Austria
TDP-43 Aggregates and Disease	Misfolded TDP-43 transmits intercellularly via large seeding particles, and is toxic intracellularly via small oligomers	<b>Neil Cashman</b> UBC, Canada
Panel Q&A of Session Speakers <i>Chair: Christian Haass, DZNE, LMU, Germany</i>		
<b>17:00</b>		
Reception in the foyer with local wine and beer specialties		
<b>17:30</b>		
From Data to Dialogue: Toasting to Better Science Conversations <i>Laura Lindenfeld, Alan Alda Center for Communicating Science, USA</i>		
<b>18:30 – 22:00</b>		
Dinner We will have a seated BBQ dinner, accompanied by fitting local wines! Depending on the weather, we will be on the hotel terrace, or in an adjacent room.		
<b>END OF THE FIRST DAY</b>		

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**TUESDAY  
MAY 05<sup>TH</sup>**

<b>8:00</b>		
Joint Breakfast, Exhibition & Poster Viewing		
<b>PANEL 9:00 – 10:00</b>		
New MoA	Amisulpride derivative as novel drug in tau-associated neurodegenerative diseases	<b>Josephine Labus</b> MHH, Germany
Clearing toxic protein aggregates	Detangling toxic aggregates	<b>Dieter Willbold</b> Priavoid, Germany
Therapeutic Improvements	Delivering $\alpha$ -synuclein antibodies into the brain via the BrainTransporter™ technology	<b>Fredrik Eriksson</b> Bioarctic, Sweden
<p><b>Panel Q&amp;A of Session Speakers</b> Chair: <i>Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany</i></p>		
<b>10:00 – 11:00</b>		
<p>Coffee Break, Exhibition &amp; Poster Session (Presenters will be at their posters.) Time for One on One Meetings</p>		
<b>11:00 – 11:30</b>		
<p><b>On the trail of protein aggregates: using RT-QuIC to detect <math>\alpha</math>-synuclein aggregates in salivary gland biopsies</b> Chair: <i>Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany</i></p>		
<b>PANEL 11:30 – 12:30</b>		
Blood diagnosis	Neuro-IP as a method for improvement of Alzheimer's disease diagnostic by blood tests	<b>Ingolf Lachmann</b> Roboscreen GmbH, Germany
Nasal sampling for diagnosis	Beyond CSF and Blood: Nasal fluid as a window into brain biology	<b>Sabine Mertzig</b> Noselab, Germany
Blood Diagnosis	From misfolding to medicine: SeNostic's SeedCycler enables diagnosis and drug discovery for proteopathies	<b>Joachim Glaubitz</b> SeNostic, Germany
<p><b>Panel Q&amp;A of Session Speakers</b> Chair: <i>Wiebke Jürgens-Wemheuer, Uni. Saarland, Germany</i></p>		
<b>12:30</b>		
Lunch		

# The Neuro4D Conference 2026

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**TUESDAY  
MAY 05<sup>TH</sup>**

13:30

Disease modifying therapies in Alzheimer's disease based on individual neurobiological staging  
Chair: *Oliver Peters, Charité, Germany*

PANEL 14:00 – 15:00

**New Therapeutic Option**

TRB-001, a novel  $\alpha$ -synuclein-based vaccine for the treatment and prevention of Parkinson's disease

**Achim Schneeberger**  
Tridem Bioscience,  
Austria

**Clinical Trials in AD**

BMS' disease modifying and symptomatic therapies currently in clinical development for Alzheimer's disease

**Daniel Ridley**  
BMS, UK

**Marketing approval and reimbursement**

From EMA to G-BA: Implementing anti-amyloid therapy in Germany

**Lutz Frölich**  
U. Heidelberg, Germany

Panel Q&A of Session Speakers

Chair: *Oliver Peters, Charité, Germany*

15:00

Coffee Break & Final Poster Session

15:30

Panel Diskussion:

- Is the GBA decision justified and final – and what does that mean for future AD therapy developments?
- How can the current immunotherapy be improved in terms of efficacy and safety?
- How accurate are current and developing diagnostics for neurodegenerative diseases and what are the implications for patients and therapies?
- Should new therapies focus on neuroinflammation and improvement of synaptic health?

Panel Participants: *Oliver Peters, Lutz Frölich, Neil Cashman, Wiebke Jürgens-Wemheuer, Christian Haass*

Moderator: *Andreas Köpke*

16:15

Potser price, Summary and Wrap-up of the conference

16:30

END OF THE CONFERENCE AND DEPARTURE